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Abstract
Purpose To describe the impact of chemotherapy-induced pe-
ripheral neuropathy symptoms (CIPN-sx) on breast cancer
survivors’ (BCS) perceived ability to work post-treatment.
Methods The sample included 22 chemotherapy-treated
(Ctx+) and 22 chemotherapy-naïve (Ctx−) female BCS.
Data was collected at the following three time points: baseline
(post-surgery, pre-chemotherapy), 1month (1M) post-chemo-
therapy, and approximately 1 year (1 Y) later. The presence,
frequency, number, and severity of CIPN-sx were self-
reported using the Functional Assessment of Cancer
Therapy/Gynecologic Oncology Group–Neurotoxicity ques-
tionnaire (FACT/GOG-Ntx) version 4, a validated 11-item
CIPN measure. Perceived ability to work was measured using
an item from the Functional Well-Being subscale of the
FACT/GOG-Ntx.
Results At 1 Y, more than 50 % of Ctx+ reported dis-
comfort, numbness, or tingling in their hands or feet;
weakness; or difficulty feeling small objects. The pres-
ence, number, and severity of these symptoms were cor-
related with being less able to work for Ctx+ at 1 M
but not 1 Y. Results of a regression analysis using
CIPN-sx to predict work ability found that models com-
bining (1) hand numbness and trouble feeling small ob-
jects, (2) trouble buttoning buttons and trouble feeling
small objects, (3) foot numbness and foot pain, (4) foot
numbness and trouble walking, and (5) trouble hearing
and hand pain each predicted survivors who were Bnot
at all^ able to work at 1 M.
Conclusions Unresolved CIPN-sx may play a role in
challenges working for BCS post-treatment. These find-
ings highlight the need for research to explore the impact
that CIPN-sx have on BCS’ ability to work, as well as
the development of interventions to improve work func-
tion in BCS with CIPN-sx.
Keywords Breast cancer . Chemotherapy . Peripheral
neuropathy . CIPN . Survivorship . Symptoms .Work .
Perceived occupational function
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Introduction
For the majority of adults in the U.S., work is an essential part
of life. Breast cancer survivors (BCS) are no exception; an
estimated 60–90 % of BCS return to work full-or part-time
after completing cancer treatment [1, 2], and a growing num-
ber of BCS work throughout their cancer treatment as well [3,
4]. Beyond the simple economic necessity of working, for
many survivors, work offers a vital source of self-esteem,
structure, and social support [5]. Unfortunately, for many
BCS, side effects related to their cancer treatments can inter-
fere with their ability to return to work and regain pre-
treatment levels of occupational function [6–8].
One side effect of cancer treatment that has received com-
paratively little attention in the discussion of work among
BCS is chemotherapy-induced peripheral neuropathy
(CIPN), a form of nerve damage associated with a number
of commonly used cancer therapies. Current estimates suggest
that 30 % or more of BCS receiving chemotherapy develop
some degree of CIPN during treatment depending on the
agents, regimen, and individual risk factors [9, 10]. While
research has begun to illustrate the potentially serious impact
that CIPN symptoms (CIPN-sx) can have on women’s quality
of life [11–13], ability to complete treatment [14, 15], and
ability to perform daily activities [16, 17], the impact of
CIPN-sx on survivors’ ability to work is only beginning to
be investigated.
This is troubling for several reasons. First, women make up
nearly half of the U.S. labor force [18] and more than 99 % of
cases of breast cancer in the U.S. [19]. In many of these cases,
use of neurotoxic chemotherapy is standard, putting more and
more BCS at risk for developing CIPN. Second, studies have
shown that the majority of BCS resume work after treatment
[20] but often with significant difficulty [21]. Issues ranging
from fatigue, physical limitations, and cognitive symptoms
have all been implicated in this difficulty returning to pre-
treatment levels of occupational functioning [5, 20], but the
role that CIPN-sx may play in this difficulty is unclear. This
lack of clarity is particularly troubling because 23–86 % of
BCS who develop CIPN-sx during treatment continue to re-
port CIPN-sx after treatment [22–27], when return to work is
likely. Thirdly, while a number of studies have shown that the
severity of CIPN-sx is associated with disruptions in treatment
[14, 15], poorer quality of life [28], and greater use of health
care resources [29], it is not clear whether the presence, fre-
quency, severity, or total number of CIPN-sx is the best pre-
dictor of difficulty working post-treatment.
The purpose of this analysis was to evaluate the impact that
the presence, frequency, number, and severity of CIPN-sx
have on BCS’ perceived ability to work post-treatment.
Specific aims were to (1) compare the presence, frequency,
number, and severity of CIPN-sx in BCS exposed to chemo-
therapy (Ctx+) to BCS whose treatment did not include che-
motherapy (Ctx−); (2) compare perceived ability to work be-
tween Ctx+ and Ctx− and determine whether the presence,
severity, and total number of CIPN-sx survivors reported were
associated with their ability to work during the first year post-
treatment; and (3) explore which combinations of CIPN-sx
best predict survivors’ ability to work post-treatment.
Methods
Sample and eligibility
Data for the analysis came from a recent longitudinal
study evaluating the effect of cancer and cancer treat-
ment on cognitive function in Ctx+ and Ctx− women
with non-metastatic breast cancer (i.e., stages 0–IIIc).
The original study also included demographically
matched healthy controls, as previously described
[30–32]. Healthy controls were not evaluated for CIPN-
sx and, therefore, were not included in the analysis.
Participants were recruited from the Indiana University
Melvin and Bren Simon Cancer Center’s recruitment core
and affiliated clinical sites. Approval for the study was granted
by the Indiana University Institutional Review Board. Written
informed consent was collected from all participants. Data
was collected at the following three time points: (1) baseline
(after breast surgery but before radiation, chemotherapy, or
anti-estrogen treatment), (2) approximately 1 month (1 M)
after completing chemotherapy, and (3) approximately 1 year
(1 Y) after the 1 M visit. Approximately one third of Ctx+
received neo-adjuvant chemotherapy and were surgery and
treatment naïve at baseline.
The sample for this analysis consisted of 22 Ctx− and 22
Ctx+ women with non-metastatic breast cancer, ages 69 or
younger. Exclusion criteria included a self-reported history
of prior cancer; substance abuse; and other medical, neurolog-
ical, and psychiatric risk factors with the potential to affect
central or peripheral neurological structure/function [30, 31].
All Ctx+ women were treated with standard doses of chemo-
therapy agents known to cause CIPN-sx, such as taxanes and
platinum compounds.
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Measures
Demographics and cancer treatment
Age at baseline (years), education (years), race and ethnicity
(categories), and initial stage of breast cancer (0–IIIc) were
collected by self-report at baseline. Information on partici-
pants’ exposure to chemotherapy and other treatments associ-
ated with the development of symptoms simlar to CIPN-sx
(e.g., muscle/joint pain) were collected from medical records.
Presence, frequency, number, and severity of CIPN-sx
The presence, frequency, number, and severity of CIPN-sx
were measured using the neurotoxicity subscale of the
Functional Assessment of Cancer Treatment Gynecological
Oncology Group–Neurotoxicity questionnaire (FACT/GOG-
Ntx) scale, version 4. The Ntx is an 11-item subscale of the
FACT/GOG that measures the presence and severity of sever-
al common CIPN-sx. Items ask participants to rate the degree
of sensory, motor, auditory, and functional CIPN-sx they ex-
perienced during the past week on a five-point Likert scale (0–
4), corresponding with increasing symptom severity [33, 34].
The reliability and sensitivity of the Ntx subscale for assessing
CIPN-sx has been established (Cronbach’s α = 0.64–0.86)
[35], especially in patients receiving taxanes [34]. Three
Ctx+ and four Ctx− included in the original study were ex-
cluded from the analysis because complete data on CIPN-sx
or perceived ability to work was not available. Given the
unique nature of each question, missing data was not imputed.
The presence of CIPN-sx was determined by calculating
the total number of Ctx+ and Ctx− women who reported hav-
ing a specific CIPN-sx, regardless of its severity (i.e., any
score greater than 0). The frequency of CIPN-sx was deter-
mined by converting the total number of women who reported
having each CIPN-sx at each time point into a percentage. The
total number of CIPN-sx at each time point was calculated by
tabulating the number of unique CIPN-sx participants report-
ed at each time point, regardless of their severity. The severity
of CIPN-sxwas determined by calculating mean scores for the
(a) total FACT/GOG-Ntx scale; (b) total scores for the senso-
ry, motor, hearing, and functional domains; and (c) scores for
individual symptoms in each domain at each time point.
Perceived ability to work and employment status
Participants’ perceived ability to work was measured using an
item from the Functional Well-Being subscale of the
FACT/GOG-Ntx (version 4), which asked participants to re-
spond to the statement BI am able to work (including house-
work).^ Perceived ability to work was scored on a five-point
Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat,
3 = quite a bit, 4 = very much).
To help inform the discussion about the impact of CIPN-sx
on occupational function, we also evaluated (1) the
percentage of women that were working either full-or
part-time at each time point, (2) the type of work in which
they were engaged (unskilled, semi-skilled, skilled, manage-
rial/clerical/official/sales, or professional/technical), and (3)
any change in the type of work performed from baseline to
1 Y.
Statistical analyses
Analyses were performed using SPSS, version 23 (IBM
Corporation). Descriptive statistics were used to tabulate the
presence (yes/no) and frequency (%) of CIPN-sx at each time
point. Pearson’s chi-squared tests were used to compare the
frequency of categorical demographic variables and the fre-
quency of CIPN-sx between groups at 1 M and 1 Y. For
categorical variables with fewer than five observations,
Fisher’s exact test was substituted. For categorical variables
with fewer than five observations where order mattered (i.e.,
stage of cancer and perceived ability to work), Mantel-Hanzel
chi-squared tests were used. Independent sample t-tests were
used to compare continuous demographic variables, the num-
ber of CIPN-sx reported, and total FACT/GOG-Ntx scores.
Differences in domain scores and individual items on the
FACT/GOG-Ntx were compared using Mann-Whitney U
tests, with a Benjamini-Hochberg correction to reduce the risk
of type I errors due to multiple comparisons. Differences in
ordinal responses to the work item between Ctx+ and Ctx−
were compared using ordinal regression models, using cancer
stage as a covariate. Spearman’s coefficients (Rs) were used to
identify significant correlations between the presence, severi-
ty, and number of CIPN-sx and ability to work post-treatment.
Ordinal regression models were constructed to explore the
combination of CIPN-sx that best predicted ability to work for
Ctx+ at 1 M and 1 Y. Because of the small sample size, 1 M
and 1 Y models were limited to two CIPN-sx apiece (i.e., one
predictor variable per ∼10 observations). Only the severity of
CIPN-sx was used in the analyses to minimize the potential to
inflate significance levels because of variables with shared
sources of variance. Final regression models were selected
based on their statistical significance (p value) and explanato-
ry value (pseudo r2 value). Because of the sample size, models
were also carefully screened for signs of overfitting (e.g., ini-
tial model fit <0.05, goodness of fit >0.05).
Results
Demographics
Table 1 summarizes the demographics for the sample.
Participants were predominantly middle-aged, white, and well-
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educated. Groups did not differ significantly on age, race, edu-
cation, use of radiation, amount of radiation received, use of
hormonal or biologic therapies, or exposure to other agents
commonly given during breast cancer treatment associated with
painful or neuropathy-like symptoms (Table 1). Groups differed
only on stage of cancer and use of trastuzumab.
Table 1 Sample characteristics
Ctx+ Ctx− Significance
Demographics N = 22 N = 22
Age at baseline (years, mean (SD)) 49.68 (8.0) 52.68 (9.3) 0.256
Race (%, Caucasian) 77.3 86.4 0.349
Education (years, mean (SD)) 15.59 (2.8) 15.27 (2.4) 0.684
Less than high school (<12 years, %) 4.5 4.5 –
High school (12 years, %) 9.1 9.1 –
Some college (13–15 years, %) 36.4 27.3 –
Four-year college (16 years, %) 18.2 27.3 –
More than four-year college (>16 years, %) 31.8 27.3 –
Cancer and cancer treatment
Stage of breast cancer at diagnosis (%, stages 0–3)
Stage 0 0.0 18.2
Stage 1 50.0 68.2 0.002c
Stage 2 40.9 13.6
Stage 3 9.1 0.0
Chemotherapy
Adjuvant (%) 68.2 0.0 –
Neo-adjuvant (%) 31.8 0.0 –
Received chemotherapy (any type, %) 100.0 0.0 –
Received a single neurotoxic agent during treatment (%) 95.5 0.0 –
Received two or more neurotoxic agents during treatment (%) 31.7 0.0 –
Type of chemotherapy received
Taxane (%) 95.5 0.0 –
Docetaxel (%) 54.5 0.0 –
Paclitaxel (%) 40.9 0.0 –
Platinating agent (%) 22.7 0.0 –
Carboplatin (%) 22.7 0.0 –
Received both taxane and platinum (%) 22.7 0.0 –
Total exposure to neurotoxic chemotherapy (mg/m2, mean (SD)) 1757.1 (1967.3) 0.0 –
Total exposure to a taxane (mg/m2, mean (SD)) 911.1 (491.8) 0.0 –
Amount of paclitaxel (mg/m2) 452.5 (727.6) 0.0 –
Amount of docetaxel (mg/m2) 388.7 (376.9) 0.0 –
Amount of carboplatin (mg/m2) 958.1 (1828.9) 0.0
Radiotherapy
Received radiotherapy during treatment (%) 81.8 59.1 0.099
Amount of radiation per fraction (Gy, mean (SD)) 2.07 (0.96) 1.93 (0.80) 0.717
Hormonal therapies
Aromatase inhibitor (AI; %) 27.2 45.5 0.510b
Selective estrogen receptor modulators (SERMs; %) 22.7 36.4 0.210a
Biologic agents
Trastuzamab (%) 22.7 0.0 0.048b
Other agents associated with painful and/or CIPN-like
symptoms
Biphosphanate (%) 13.6 0.0 0.233b
BC breast cancer, SD standard deviation,Ctx+womenwith breast cancer treated with surgery and/or radiation and
chemotherapy, Ctx− women with breast cancer treated with surgery and/or radiation but no chemotherapy
In some cases, totals in a particular category do not equal 100.0 % because participants may have received more
than one agent during treatment. Differences between quantitative variables were tested using independent sample
t-tests, α = 0.05. Note Values in italics are significant at α= 0.05
aDifferences between categorical variables with adequate cell counts were tested with Pearson’s chi-squared tests
(two-sided), α = 0.05
bDifferences between categorical variables with inadequate cell counts (i.e., <5 observations) were tested with
Fisher’s exact test (two-sided), α = 0.05
c Differences between categorical variables with inadequate cell counts (i.e., <5 observations) where order
mattered were tested with Mantel-Hanzel chi-squared tests (two-sided), α = 0.05
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Table 1 also details participant’s exposure to cancer
treatments associated with CIPN-sx or similar symptoms (e.g.,
muscle/joint pain).More than 95% of Ctx+ received at least one
neurotoxic agent during treatment, and almost a third received
two neurotoxic agents. Of these, all but one received a taxane
(docetaxel 54.5 %, paclitaxel 40.9 %). Mean taxane exposure
was 911 ± 492 mg/m2. Five Ctx+ who received a taxane also
received the platinum compound carboplatin. Mean platinum
exposure among Ctx+ was 958.1 ± 1828.9 mg/m2.
Presence and frequency of CIPN-sx
At baseline, Ctx+ and Ctx− did not differ significantly on the
presence, frequency, severity, or total number of CIPN-sx
(Tables 2 and 3). At 1 M, more than 50 % of Ctx+ reported
numbness, tingling or discomfort in their hands or feet; joint
pain/muscle cramps; weakness; and difficulty feeling the shape
of small objects. With the exception of three symptoms (joint
pain/muscle cramps, trouble walking, and trouble hearing),
Ctx+ reported CIPNmore frequently than Ctx− for all symptoms
we evaluated at 1 M. At 1 Y, the frequency and type of CIPN-sx
reported by Ctx+was very similar to 1M, with more than half of
Ctx+ reporting numbness, tingling, or discomfort in their hands
or feet; joint pain/muscle cramps; and weakness.
Between 1 M and 1 Y, the frequency of some CIPN-sx
increased slightly between for Ctx+. At 1 Y, a slightly higher
percentage of Ctx+ reported hand numbness/tingling (63.6 vs.
59.1 %), foot numbness/tingling (57.1 vs. 54.5 %), joint
pain/muscle cramps (72.7 vs. 68.2 %), trouble buttoning but-
tons (33.8 vs. 31.8 %), and difficulty walking (38.1 vs.
27.3 %) than at 1 M.
Total number of CIPN-sx
At 1 M, Ctx+ reported an average of 5.59 ± 3.5 CIPN-sx,
compared to 3.14 ± 2.0 CIPN-sx for Ctx− (p = 0.006;
Table 2). A year later, the total number of CIPN-sx Ctx+ re-
ported was virtually unchanged; at 1 Y, Ctx+ reported an av-
erage of 5.18 ± 3.5 symptoms and Ctx− reported 3.41 ± 2.3
(p = 0.049).
Table 2 Frequency and total number of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) at baseline, 1-month, and 1-year time
points
Frequency of CIPN-sxa Baseline (pre-treatment) One-month time pointb One-year time pointc
Ctx+ Ctx− Ctx+ Ctx− Ctx+ Ctx−
%a %a Significance %a %a Significance %a %a Significance
Sensory symptoms
Numbness/tingling in hands 18.2 18.2 1.000e 59.1 13.6 0.002d 63.6 13.6 0.001d
Numbness/tingling in feet 9.1 18.2 0.664e 54.5 9.1 0.001d 57.1 18.2 0.008d
Discomfort in hands 13.6 22.7 0.698e 54.5 18.2 0.012d 52.4 27.3 0.092d
Discomfort in feet 18.2 27.3 0.472d 59.1 27.3 0.033d 59.1 45.5 0.365d
Motor symptoms
Joint pain/muscle cramps 50.0 50.0 1.000d 68.2 72.7 0.741d 72.7 71.4 0.924d
Feeling weak all over 22.7 22.7 1.000d 77.3 36.4 0.006d 59.1 22.7 0.014d
Trouble walking 18.2 36.4 0.176d 36.4 54.5 0.226d 38.1 59.1 0.169d
Auditory symptoms
Trouble hearing 18.2 40.9 0.099d 27.3 45.5 0.210d 27.3 54.5 0.066d
Ringing/buzzing in ears 9.1 0.0 0.448e 36.4 4.5 0.021e 33.3 4.5 0.046e
Functional symptoms
Trouble buttoning buttons 9.1 0.0 0.448e 31.8 0.0 0.009e 33.3 0.0 0.004e
Trouble feeling the shapeof small objects inhand 9.1 27.7 0.412e 54.5 31.8 0.128d 31.8 27.3 0.741d
Total number of CIPN-sx
Mean (SD) 1.95 (2.4) 2.59 (2.2) 0.366f 5.59 (3.5) 3.14 (2.0) 0.006f 5.18 (3.5) 3.41 (2.3) 0.049f
Note Values in italics are significant at α= 0.05
Ctx+ women with breast cancer treated with surgery and/or radiation and chemotherapy, Ctx− women with breast cancer treated with surgery and/or
radiation but no chemotherapy, SD standard deviation
a Frequency is defined as the percentage of Ctx+ or Ctx− reporting this CIPN-sx in the last 7 days of this time point, regardless of severity
b One month following chemotherapy completion or yoked interval for Ctx−
c One year following 1-month time point
d Differences between percentage of Ctx+ and Ctx− reporting individual CIPN-sx with adequate cell counts were tested using Pearson’s chi-squared
tests, α = 0.05
eDifferences between nominal variables with inadequate cell counts (i.e., <5 observations) were tested with Fisher’s exact test (two-sided), α = 0.05
f Differences in the total CIPN-sx reported by Ctx+ and Ctx− at each time point were tested using independent measured t test (α = 0.05)
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Severity of CIPN-sx
At 1 M, Ctx+ reported significantly more severe functional
CIPN-sx than Ctx− (p = 0.007). In addition, total scores on the
sensory domain just missed the cutoff for statistical signifi-
cance after adjusting for multiple comparisons (p = 0.006;
Table 3). Inspection of individual FACT/GOG-Ntx scores re-
vealed that Ctx+ had more severe numbness/tingling in their
hands (p = 0.002) and feet (p = 0.001), hand discomfort
(p = 0.012), weakness (p = 0.003), ringing/buzzing in their
ears (p = 0.009), and trouble buttoning buttons (p = 0.004)
than Ctx− after treatment.
At 1 Y, while total and sensory FACT-GOG/Ntx scores
were not significantly different between Ctx+ and Ctx−,
Ctx+ continued to report more severe functional CIPN-sx than
Ctx− (p = 0.004), including more severe numbness/tingling in
their hands (p = 0.001) and feet (p = 0.013) and trouble but-
toning buttons (p = 0.002; Table 3).
Employment status and perceived ability to work
At baseline, 1 M, and 1 Y, all 44 Ctx+ and Ctx−were working
part-or full-time (Fig. 1). Of these, 92.4 % of Ctx+ and more
than 70 % of Ctx− were working in positions classified as
either professional/technical or managerial/official/clerical/
sales in nature (Fig. 2). Over the course of the study (i.e.,
BL to 1 Y), there was virtually no change in the type of work
participants performed (data not shown).
Compared to survivors who reported being Bvery^
able to work at 1 M, having received chemotherapy
during treatment significantly predicted being only
Bsomewhat^ (p = 0.00), Ba little bit^ (p = 0.00), or Bnot
at all^ (p = 0.03) able to work, after controlling for
differences in cancer stage between Ctx+ and Ctx− (data
not shown). Similarly, at 1 Y compared to women who
were very able to work, having received chemotherapy
during treatment was also significantly associated with
being only Ba little^ or somewhat able to work, after
controlling for stage of cancer. This difference was espe-
cially evident at 1 M, where 50 % of Ctx+ reported
being only somewhat, a little bit, or not at all able to
work, compared to just 9.1 % of Ctx− survivors.
Association between presence, severity, and number
of CIPN-sx and ability to work
At 1 M, the severity of the following five combinations of
CIPN-sx were correlated with BCS’ work ability: hand
numbness/tingling (Rs = −0.483; p = 0.023), hand discom-
fort (Rs = −0.511; p = 0.015), weakness (Rs = −0.557;
p = 0.007), trouble hearing (Rs = −0.454; p = 0.034), and
difficulty feeling the shape of small objects (Rs = −0.463;
p = 0.030). In addition, at 1 M the presence of any hand
discomfort (Rs = −0.455; p = 0.033), weakness
(Rs = −0.603; p = 0.003), trouble hearing (Rs = −0.501;
p = 0.018), or trouble feeling the shape of small objects
in hand (Rs = −0.433; p = 0.044), regardless of severity,
were also significantly correlated with work scores among
Ctx+, as was the number of CIPN-sx reported at 1 M
(Rs = −0.526; p = 0.012).
At 1 Y, only the presence of weakness (regardless of sever-
ity) was associated with perceived work ability for Ctx+
(Rs = −0.478; p = 0.024).
Using the severity of CIPN-sx to predict work ability
post-treatment
Results of the exploratory analysis using ordinal regression
identified five models that predicted Ctx+ who were not at
all able to work at 1 M, which are presented in Table 4: (1)
hand numbness and trouble feeling the shape of small ob-
jects (Wald χ2(1) = 11.39; cumulative OR = 0.008;
Nagelkerke r2 = 0.500), (2) trouble buttoning buttons and
trouble feeling the shape of small objects (Wald
χ2(1) = 12.99; OR = 0.004; Nagelkerke r2 = 0.567), (3)
foot numbness and foot pain (Wald χ2(1) = 7.65;
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OR = 0.031; Nagelkerke r2 = 0.644), (4) foot numbness
and trouble walking (Wald χ2(1) = 10.67; OR = 0.003;
Nagelkerke r2 = 0.724), and (5) trouble hearing and hand
pain (Wald χ2(1) = 12.02; OR = 0.005; Nagelkerke
r2 = 0.583). At 1 Y, no combination of CIPN-sx signifi-
cantly predicted work ability for Ctx+ (data not shown).
Baseline 1 Month 1 Year Baseline 1 Month 1 Year
Ctx+ Ctx-
Not at all 0.0 13.6 0.0 0.0 0.0 0.0
A little bit 4.5 4.5 4.5 4.5 0.0 0.0
Somewhat 13.6 31.8 4.5 4.5 9.1 0.0
Quite a bit 45.5 31.8 40.9 22.7 27.3 18.2
Very much 36.4 18.2 50.0 68.2 63.6 81.8
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Fig. 2 Perceived ability to work
at baseline, 1-month, and 1-year
time points. The figure illustrates
the percentage of Ctx+ and Ctx−
who reported being not at all, a
little bit, somewhat, quite a bit,
and very much able to work
(including housework) at each
time point
Table 4 Ordinal regression models using the severity of CIPN-sx to predict perceived work ability in chemotherapy-treated (Ctx+) breast cancer
survivors approximately 1 month after treatment (N = 22)
Variable (reference) Coefficient SE Wald p value 95 % CI Cumulative
odds ratio
Nagelkerke r2
Lower Upper
Combination 1, hand symptoms
Ability to work (not at all) −4.24 1.26 11.39 0.001 −6.70 −1.78 0.008 0.500
Hand numbness (somewhat) −4.50 1.89 5.64 0.018 −8.21 −.786
Trouble feeling the shape of small objects (very much) 7.28 3.13 5.43 0.020 1.16 13.41
Combination 2, hand symptoms
Ability to work (not at all) −5.50 1.53 12.99 0.000 −8.50 −2.51 0.004 0.567
Trouble buttoning buttons (a little bit) −3.79 1.60 5.60 0.018 −6.93 −0.65
Trouble feeling the shape of small objects (somewhat) −4.48 1.87 5.75 0.017 −8.15 −0.82
Combination 3, lower extremity
Ability to work (not at all) −3.47 1.26 7.65 0.006 −5.94 −1.01 0.031 0.644
Foot numbness (somewhat) −5.98 2.36 6.40 0.011 −10.6 −1.35
Foot pain (quite a bit) 9.36 4.21 4.95 0.026 1.12 17.60
Combination 4, lower extremity
Ability to work (not at all) −5.79 1.77 10.67 0.001 −9.26 −2.32 0.003 0.724
Foot numbness (quite a bit) −4.68 1.83 6.52 0.011 −8.28 −1.09
Trouble walking (quite a bit) 4.40 2.12 4.33 0.037 0.26 8.55
Combination 5, hearing and hand pain
Ability to work (not at all) −5.32 1.54 12.02 0.001 −8.33 −2.31 0.005 0.583
Hand pain (very much) −3.94 1.72 5.26 0.022 −7.32 −0.57
Trouble hearing (a little bit) −4.31 1.85 5.45 0.020 −7.94 −0.69
Values represent the results of separate univariate ordinal regression models using the severity of individual CIPN-sx as predictor variables and self-
reported ability to work (including housework) as the dependent variable (categories: not at all, a little bit, somewhat, quite a bit, very much). To ensure
that models predicted poor work performance based on the severity CIPN-sx, CIPN-sx were reverse coded (i.e., 0 = very much, 1 = quite a bit,
2 = somewhat, 3 = a little bit, 4 = not at all). Note Values in italics are significant at α= 0.05
SE standard error, CI confidence interval
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Discussion
There is growing evidence that CIPN-sx pose a risk to
BCS not only during cancer treatment but after as well
[24–26, 36–41]. Previous research has linked CIPN-
sx with poorer quality of life and decreased ability to
function [28], but this is one of the first studies to address
the question of whether CIPN-sx impact work in BCS
post-treatment [28]. Results of this study add to the grow-
ing evidence showing the persistence of CIPN-sx after
treatment [25, 26, 36], and extend these findings to the
context of occupational function, demonstrating a clear
link between the presence, frequency, number, and sever-
ity of CIPN-sx and BCS’ self-reported inability to work
following treatment. Results of our analysis also suggest
that (1) the total number of CIPN-sx Ctx+ report, regard-
less of their severity, may be a useful predictor of diffi-
culty working and that (2) painful and non-painful CIPN-
sx affecting the hands or feet (with or without treatment-
related hearing deficits) may predict work difficulty for
Ctx+ 1 M post-treatment.
Presence and frequency of CIPN-sx An important finding
from our analysis was that the pattern of CIPN-sx reported by
Ctx+ approximately a year post-treatment was very similar to
the pattern reported at 1 M. In the context of work, this has
important implications because it raises the possibility that the
CIPN-sx survivors present with immediately after treatment
may be a reliable indicator of the CIPN-sx that will continue to
interfere with a survivor’s ability to work during the critical
first year of survivorship. Research in larger samples is needed
to test this hypothesis.
Total number of CIPN-sx A second potentially important
finding from our analysis was that the number of CIPN-sx
Ctx+ reported, independent of their severity, appeared to pre-
dict ability to work post-treatment. The majority of studies
have used either the presence [14, 15, 29] or severity of
CIPN-sx as the primary lens for evaluating CIPN-related out-
comes [41]. While our results suggest that both are likely to
predict work ability, the number of CIPN-sx patient’s experi-
ence itself may also be disruptive to work. On average, Ctx+
in our sample reported five different CIPN-sx at both post-
treatment time points. As with other studies, when we looked
at the severity of these CIPN-sx, in many cases, we observed a
pattern of one or two severe CIPN-sx and several milder
symptoms [41]. Because this mixed severity pattern is com-
mon, it will be important to clarify whether the number of
CIPN-sx survivors report is just as predictive of difficulty
working as severity of each symptom. This is not only because
the severity of CIPN-sx can vary but also because CIPN-sx
often grow less severe over time [10], which could lead
providers to overlook the potentially serious impact that a
number of milder CIPN-sx could have on BCS’ ability to
work.
Association between the severity of CIPN-sx and ability to
work at 1 M During our regression analyses, we identified
several combinations of CIPN-sx that were predictive of
Ctx+ that were less able to work at 1 M. These included
two combinations of sensory CIPN-sx affecting the
hands, two combinations of CIPN-sx affecting the feet,
and the combination of hearing loss and hand discomfort
(Table 4). These findings are consistent with the few
studies of CIPN in which work was considered [28]
and make sense intuitively. In particular, the finding that
sensory symptoms that interfere with women’s ability to
feel the shape of objects or button buttons were associ-
ated with difficulty working was not surprising. These
combinations of CIPN-sx point to potential phenotypes
for CIPN-related work interference. It is important to
note that several other symptoms such as weakness and
joint pain/muscle soreness also predicted inability to
work at 1 M in several of our models but were not
included because of lack of model fit given our sample
size. Statistical considerations notwithstanding, it is clear
that symptoms such as joint pain/muscle soreness and
weakness have the potential to impact work and should
be included in future studies of CIPN-sx and work.
Association between the severity of CIPN-sx and ability to
work at 1 Y There are several reasons that may explain why
we did not observe a stronger effect of CIPN-sx on perceived
work ability at 1 Y. First, the percentage of Ctx+ who reported
being Bvery much^ or Bquite a bit^ able to work after treat-
ment rose from 41.4 % at 1 M to 90.9 % at 1 Y (Fig. 2a). At
the same time, the type, frequency, severity, and number of
CIPN-sx Ctx+ reported remained relatively constant. This
combination of improving ability to work in the face of rela-
tively stable CIPN-sx suggests that while BCS may continue
to experience CIPN post-treatment, the impact of these symp-
toms on work may lessen over time as BCS acclimate to their
symptoms and/or develop coping strategies.
Finally, it is important to note that while the lack of treat-
ments for CIPN-sx is problematic on many fronts, it is partic-
ularly concerning in the context of work. Recently, several
groups have had some success treating the painful component
of CIPN-sx non-invasively using devices such as scrambler
therapy [42], as well as several oral or topical agents [10].
These successes raise the question of whether strategies like
these could be used to address painful CIPN-sx before they
can disrupt cancer survivors’ transition back to usual work
activities.
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Limitations
While this study provides a useful starting point for fu-
ture research exploring the impact of CIPN-sx on breast
cancer survivor’s ability to work post-treatment, our re-
sults need to be considered in light of several limitations.
First, the sample for this analysis was small; larger sam-
ples will be needed to validate these findings and explore
which combinations of CIPN-sx best predict survivor’s
ability to work. Secondly, we did not have access to
detailed information on potential risk factors for CIPN
such as osteoarthritis, and the size of our sample
prevented us from including symptoms such as depres-
sion as covariates in our analysis, both of which should
be included in future studies. Third, our analysis relied
on a single item to evaluate perceived ability to work
post-treatment. While this item provided a useful lens
for looking at the impact of CIPN-sx on work, clearly,
more stringent and varied measures of work including
absenteeism, productivity, and performance on job-
specific tasks will be needed to understand the occupa-
tional impact of CIPN-sx. In addition, we did not have
access to objective measures of CIPN, which would have
provided valuable insight into structural or functional
changes in nerves that may help to explain perceived
difficulties working. Fourth, our sample was racially/
ethnically homogeneous; more diverse cohorts will be
needed to understand whether the impact of CIPN-sx
on work outcomes differs by race, ethnicity, or culture.
Finally, our sample was approximately 10 years younger
than the median age of BCS in the USA. The reason for
this was that the study upon which our analysis was
based enrolled only women younger than age 70. As
such, while our sample is representative of working-age
BCS, studies in older survivors that continue work past
the current typical age of retirement will be needed to
explore the impact of CIPN-sx on work in this popula-
tion fully.
Conclusion
The increasing reliance on neurotoxic chemotherapy to treat
many forms of breast cancer means that clinicians and patients
will need to carefully consider how best to balance the benefits
and risks of treatment, including the potential impact of CIPN-
sx on their ability to work. Our findings suggest that clinicians
should remain vigilant for CIPN-sx that may interfere with
women’s ability to work during the first year post-treatment,
when many survivors return to work. Women who continue to
experience CIPN-sx post-treatment (especially in the context
of other symptoms that can interfere with work such as pain,
fatigue, or cognitive disruption) may need to be referred to
physical or occupational therapy to minimize the negative
impact of CIPN-sx on work.
This concern may be especially pertinent in the modern
workplace, with its growing reliance on tactile technologies
such as keyboards and touch screens, which require users to
be able to effortlessly tap, touch, type, and glide their way
through their workday. Identifying the specific CIPN-sx and
dimension of the symptom experience (i.e., presence, frequen-
cy, severity, or total number) that best predict difficulty work-
ing is an essential first step towards developing interventions
to reduce their impact on work for BCS with CIPN.
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